Dupixent (dupilumab)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION		
LAST NAME:	**FIRST NAME:**	
PHONE NUMBER:	**DATE OF BIRTH:**	
STREET ADDRESS:		
CITY:	**STATE:**	**ZIP CODE:**
PATIENT INSURANCE ID NUMBER:		

☐ **MALE** ☐ **FEMALE** **HEIGHT (IN/CM):** _____ **WEIGHT (LB/KG):** _____ **ALLERGIES:** _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION		
LAST NAME:	**FIRST NAME:**	
PRESCRIBER SPECIALTY:	**EMAIL ADDRESS:**	
NPI NUMBER:	**DEA NUMBER:**	
PHONE NUMBER:	**FAX NUMBER:**	
STREET ADDRESS:		
CITY:	**STATE:**	**ZIP CODE:**
REQUESTER (if different than prescriber):	**OFFICE CONTACT PERSON:**	

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	**FREQUENCY:**	**LENGTH OF THERAPY/REFILLS:**	**QUANTITY:**
☐ **NEW THERAPY** ☐ **RENEWAL** **IF RENEWAL:** DATE THERAPY INITIATED: DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page

Dupixent (dupilumab)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? ☐ **YES** (if yes, complete below) ☐ **NO**		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE)**:**	**DURATION OF THERAPY** (SPECIFY DATES)**:**	**RESPONSE/REASON FOR FAILURE/ALLERGY:**

2. LIST DIAGNOSES:	**ICD-10:**
☐ **Moderate to severe atopic dermatitis** ☐ **Moderate-to-severe persistent asthma** ☐ **Chronic rhinosinusitis with nasal polyps** ☐ **Eosinophilic Esophagitis** ☐ **Prurigo nodularis** ☐ **Chronic obstructive pulmonary disease** ☐ Other diagnosis: _____ ICD-10 Code(s):	

3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.

Is patient going to be using drug in combination with a clinical trial? ☐ **Yes** ☐ **No**

Is prescriber one of the following or in consultation with one of the following: ? □ **Yes** □ **No** ***Please provide documentation.***
□ **Allergist**
□ **Immunologist**
□ **Dermatologist**
□ **Pulmonologist**
□ **Otolaryngologist**
□ **Gastroenterologist**

Will patient use Dupixent in combination with one of the following? □ **Yes** □ **No**
□ **Nucala(mepolizumab), Cinqair (resilizumab), Fasenra (benralizumab), Xolair(omalizmab), Benlysta(bemlimumab), Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire (tezepelumab)]**

Will Dupixent(dupilumab) be used in combination with Cibinqo(abrocitinib), Olumiant(baracitinib), RinvoqER(upadacitinib) ,Opzelura(ruxolitinib) or Adbry(tralokinumab)? □ **Yes** □ **No**

<u>For Initial Request of Atopic Dermatitis</u>, answer the following:

Has the patient had the diagnosis of atopic dermatitis for at least 12 months? □ **Yes** □ **No** ***Please submit documentation.***

Does the patient have atopic dermatitis on at least 10% or more of their body surface area? □ **Yes** □ **No** ***Please submit documentation.***

Dupixent (dupilumab)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Has the patient tried at least two different topical steroids? □ Yes □ No *Please submit documentation.*

If patient has not had at least 2 different topical steroids, has the patient tried at least one topical steroid AND one topical calcineurin inhibitor (tacrolimus or pimecrolimus)? □ Yes □ No *Please submit documentation.*

If patient has not had at least 2 different topical steroids, has the patient tried at least one topical steroid AND Eucrisa(crisaborole)? □ Yes □ No *Please submit documentation.*

If patient has not had at least 2 different topical steroids, has the patient tried at least one topical steroid AND Zoryve(roflumilast)? □ Yes □ No *Please submit documentation.*

If patient has not had at least 2 different topical steroids, has the patient tried at least one topical steroid AND Vtama(tapinarof)? □ Yes □ No *Please submit documentation.*

For Renewal of Atopic Dermatitis:

Does patient continue to demonstrate a positive clinical response? □ Yes □ No *Please submit documentation.*

Is prescriber a dermatologist or allergist? □ Yes □ No

Will Dupixent(dupilumab) be used in combo w Cibinqo(abrocitinib), Olumiant(baracitinib), RinvoqER(upadacitinib), Opzelura(ruxolitinib), or Adbry(tralokinumab)? □ Yes □ No

For diagnosis of Moderate-to-severe persistent asthma, answer the following:

Has the patient had moderate to severe persistent asthma for at least one year? □ Yes □ No

Is patient's asthma characterized as corticosteroid dependent asthma? □ Yes □ No

Is patient's asthma characterized as eosinophilic phenotype asthma? □ Yes □ No

Does the patient have COPD or other concurrent lung disease? □ Yes □ No

Is the patient a current smoker? □ Yes □ No

Has the patient quit smoking in the last 6 months? □ Yes □ No

Is the patient a former smoker with a smoking history of more than 10 pack years? □ Yes □ No

Has the patient ever had one of the following:

a.) Blood eosinophil count = 150mcL or greater ? □ Yes □ No *Please submit documentation*

b.) Sputum eosinophil count = 3% or greater ? □ Yes □ No *Please submit documentation*

Dupixent (dupilumab)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Has the patient been on stable medium-to- high dose of an inhaled glucocorticoid (i.e. fluticasone 250 mcg or greater) for at least ONE month? □ Yes □ No *Please submit chart notes*
Has the patient been on stable daily dose of inhaled long-acting beta agonist (i.e salmeterol 50 mcg or greater twice daily) for at least ONE month? □ Yes □ No *Please submit chart notes*

Has the patient received at least ONE systemic (oral or parenteral) steroid burst for worsening asthma, in the past 2 years? □ Yes □ No

Has the patient been hospitalized or visited an emergency care center at least once for worsening asthma, in the past 2 years? □ Yes □ No

Has the patient been receiving regular MAINTENANCE systemic corticosteroids in the past 6 months? □ Yes □ No

Has the patient been receiving oral prednisone or prednisolone at a dose of 5-35 mg per day, or equipotent steroid equivalent for the past 4 weeks? □ Yes □ No *Please submit chart notes*

Has the patient been using high dose inhaled fluticasone at a stable dose >500 mcg per day, or equipotent steroid equivalent for the past 4 months? □ Yes □ No *Please submit chart notes*

Has the patient been using one of the following long-acting beta2 agonist AND/OR leukotriene-receptor antagonist for the past 3 months? □ Yes □ No

For diagnosis of chronic rhinosinusitis with nasal polyps, answer the following:
Does patient have at least a 2 month use of a nasal steroid? □ Yes □ No *Please submit documentation.*

For diagnosis of Eosinophilic Esophagitis, please answer the following:
Has patient had a previous trial with a proton-pump inhibitor(PPI)? □ Yes □ No *Please submit documentation.*
Has patient had a 12 week trial and failure with Eohilia(budesonide oral suspension)? □ Yes □ No *Please submit documentation.*
Does patient have symptoms of dysphagia? □ Yes □ No
Does patient have greater than or equal to 15 (eos/hpf) intraepithelial eosinophils/ high-power field (eos/hpf)? (lab report. □ Yes □ No *Please submit documentation.*
Does the patient have other causes of esophagitis? □ Yes □ No

For diagnosis of Prurigo Nodularis, please answer the following:
Has patient had chronic pruritus lasting ≥6 weeks? □ Yes □ No *Please submit documentation.*

Does patient have history and/or signs of repeated scratching, picking, or rubbing (eg, excoriations and scars)? □ Yes □ No *Please submit documentation.*

Does patient have presence of multiple pruriginous lesions, including firm nodules? □ Yes □ No *Please submit documentation.*

Dupixent (dupilumab)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Has the patient tried at least 2 different medium-to-super-potent topical steroids? □ Yes □ No
Please submit documentation.

Has the patient tried at least one medium-to-super-potent topical steroid AND one topical calcineurin inhibitor (tacrolimus or pimecrolimus)? □ Yes □ No *Please submit documentation.*

Has the patient tried oral psoralen in combination with phototherapy AND at least one medium-to-super-potent topical steroid? □ Yes □ No *Please submit documentation.*

Has patient tried excimer laser AND at least one medium-to-super-potent topical steroid? □ Yes □ No *Please submit documentation.*
Has patient tried cryotherapy AND intralesional steroids? □ Yes □ No *Please submit documentation.*
Has patient tried at least one oral DMARD such as methotrexate or cyclosporine? □ Yes □ No
Please submit documentation.

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

_____

_____

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

FAX THIS FORM TO: 800-424-7640
MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP-4201
P.O. Box 64811
St. Paul, MN 55164-0811
Phone: 877-228-7909